A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

Inclusion Criteria:

• Gradual and progressive change in memory function reported by the participant orinformant for ≥6 months.

• A mini mental state examination (MMSE) score of 20 to 28 (inclusive) at screening.

• Have an amyloid PET scan result from central read, consistent with the presence ofamyloid pathology.

Exclusion Criteria:

• Have significant neurological disease affecting the central nervous system otherthan AD, that may affect cognition or ability to complete the study, including butnot limited to, other dementias, serious infection of the brain, Parkinson'sdisease, multiple concussions, or epilepsy or recurrent seizures, except febrilechildhood seizures.

• Has current serious or unstable illnesses including cardiovascular, hepatic, renal,gastroenterologic, respiratory, endocrinologic, neurologic (other than AD),psychiatric, immunologic, or hematologic disease and other conditions that, in theinvestigator's opinion, could interfere with the analyses in this study.

• A life expectancy of <24 months.

• Contraindication to MRI or PET scans

• Have had prior treatment with a passive anti-amyloid immunotherapy.

• Have a presence or history of malignant neoplasms within the past 5 years prior toVisit 1.

Exceptions:

• non-metastatic basal- or squamous-cell skin cancer

• Stage 0 non-invasive carcinoma of the cervix

• Stage 0 non-invasive prostate cancer, or

• other cancers with low risk of recurrence or spread